PD-Check: Precision Parkinson's Diagnosis
Breakthrough Parkinson's Test
Non-invasive Screening
Objective assessment without uncomfortable procedures or radiation exposure.
Early Detection
Identify subtle markers years before motor symptoms appear.
Real-time Monitoring
Track disease progression with precision for timely treatment adjustments.
Clinical Accuracy
AI-driven analysis delivers results with medical-grade reliability.
Improved Outcomes
Improve patient outcomes with timely treatment. Our test supports better management.
Accurate Results
Experience precise and reliable results. Reduce diagnostic uncertainty.
PD-Scan: Revolutionizing Parkinson's Detection
A New Era in Neurological Diagnostics
Building on our legacy of FDA-cleared advanced eye-tracking technology, Spryson is preparing to introduces PD-Scan – a groundbreaking non-invasive diagnostic tool for Parkinson’s Disease. Our pursuit of FDA Breakthrough Status marks a pivotal moment in our mission to transform neurological care.
PD-Scan represents a quantum leap in diagnostic capabilities, enabling early detection and continuous monitoring with unprecedented precision. By providing clinicians with real-time, actionable insights, we’re not just improving diagnosis – we’re enhancing patient outcomes and reshaping the future of neurological care through cutting-edge healthcare technology.
This product is currently under FDA review and is not yet approved for sale. Reservations are non-binding and do not guarantee delivery. Availability is subject to FDA clearance.
PD-Check: Pioneering Precision. Empowering Lives.
Join us in revolutionizing neurological diagnostics and improving millions of lives worldwide.
Detecting Parkinson’s Disease with Patented Biomarkers with Eye-Tracking Technology
Innovative Approach with NeuroAI
• High-Definition Eye-Tracking: Utilizing best-in-class, FDA-cleared eye-tracking technology to analyze eye movement patterns linked to neurological functions.
• Identifying PD Biomarkers: Detecting early Parkinson’s disease biomarkers through subtle changes in saccades, smooth pursuit, and fixation stability.
• Real-Time Predictive Analysis: AI-driven insights provide real-time diagnostic data to aid in early detection and personalized treatment planning.
Groundbreaking Research
- Collaborative Study: In partnership with the University of Michigan, advancing research on eye movement abnormalities as early indicators of Parkinson’s disease.
- Large-Scale Data Collection: Leveraging extensive datasets to refine algorithms for increased diagnostic accuracy.
- Clinical Validation: Ensuring robust clinical validation to support FDA clearances.
- World’s biggest PD Study: advancing research on eye movement abnormalities as early indicators of Parkinson’s.
Biomarkers Sensitivity and Specificity Approaching 100%
Impact on Parkinson’s Disease Care
Clinical Impact: Transforming Patient & Physician Experiences
For Patients
Earlier & More Accurate Diagnoses:
- Reduces Diagnostic Delays: NeuroAI enables timely access to therapeutics, significantly reducing the current 3-5 year delay for Parkinson’s confirmation.
- Improved Patient Outcomes: Early diagnosis allows for proactive intervention, improving patient prognosis and overall quality of life.
- Ruling Out Parkinson’s Disease (PD): NeuroAI’s advanced diagnostic capabilities can accurately rule out PD, reducing misdiagnoses and unnecessary treatments.
Non-Invasive Testing:
- Quick and Painless Experience: Non-invasive eye-tracking provides a stress-free diagnostic process, empowering patients to take control of their health.
- Proactive Care and Cost Efficiency: Early detection reduces the need for more expensive and invasive testing, lowering overall healthcare costs.
For Physicians
Seamless Integration:
- Effortless Workflow Integration: NeuroAI seamlessly incorporates into primary care and neurology workflows, minimizing disruption and increasing efficiency.
- User-Friendly Interface: Intuitive platform design ensures quick onboarding and ease of use, allowing clinicians to focus on patient care.
Enhanced Diagnostic Accuracy:
- Data-Driven Decision Making: NeuroAI provides quantitative metrics and predictive analytics, increasing diagnostic accuracy and confidence.
- Optimized Patient Management: Tailored medication plans and personalized treatment strategies enhance patient outcomes and satisfaction.
For Caregivers
For Caregivers:
Early & Clear Information:
- Reduced Uncertainty and Anxiety: Early and accurate diagnoses offer clear information and guidance, helping caregivers better understand the patient’s condition.
- Informed Long-Term Care Planning: Access to early diagnostic data enables proactive long-term care strategies, ensuring a higher quality of life for patients.
- Emotional and Financial Relief: Clear, early diagnoses reduce the emotional and financial burdens associated with delayed disease progression.
For Researchers
For Researchers:
Real-World Impact and Evidence Generation:
- Large-Scale Data Collection: NeuroAI’s innovative diagnostics enable extensive data collection, facilitating evidence-based research and enhancing study power.
- Clinical Validation and Publication Opportunities: Collaborate on groundbreaking research and clinical studies, contributing to high-impact publications and advancing neurological science.
Advancing Neurological Science and Treatment:
- Supporting the Search for Cures: By providing earlier and more accurate diagnoses, NeuroAI accelerates patient stratification and target identification, directly supporting the discovery of new therapeutic approaches and potential cures.
- Predictive Biomarker Discovery: Advanced analytics enable the identification of predictive biomarkers, driving personalized medicine and improving clinical trial outcomes.
- Innovative Research Collaboration: Partner with leading academic institutions, research centers, and pharmaceutical companies to accelerate drug development and neurotherapeutic innovations.
Why Parkinson's Detection Matters
Increasing Cases
In the US, 90,000 new cases are diagnosed each year. Early screening benefits 102 million+ Americans over 55.
Diagnostic Challenges
Current misdiagnosis rates are high, especially in early stages. Up to 30% of cases are misdiagnosed.
Global Impact
Over 8.5 million people live with Parkinson's globally. Over 1 million new cases are diagnosed annually.
Large Screening Population
1.5 billion+ people globally over 55 should be screened yearly. Early detection is key.
Explosive Growth & Market Expansion
European Union
Preparing regulatory submissions.
United Kingdom
Strategic partnerships are forming for market entry.
MDSAP Regions
Targeting Australia, Brazil, Canada, and Japan.
China
Exploring opportunities with local partners.
Next Steps
Secure Your Priority Access
Be among the first to experience PD-Scan once FDA clearance is obtained. Join the waiting list today and reserve your spot for exclusive early access
Stay Informed and Involved
We’re making great strides, and we want you to be a part of our journey. Get the latest updates on our progress and be the first to know about new developments.